Compare HDL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | GLUE |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2024 | 2021 |
| Metric | HDL | GLUE |
|---|---|---|
| Price | $18.32 | $17.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 2.0K | ★ 925.7K |
| Earning Date | 11-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.04 | ★ 0.25 |
| Revenue | ★ $820,865,000.00 | $181,538,000.00 |
| Revenue This Year | $11.19 | $81.52 |
| Revenue Next Year | $13.37 | N/A |
| P/E Ratio | ★ $58.13 | $68.97 |
| Revenue Growth | 8.02 | ★ 1112.27 |
| 52 Week Low | $16.30 | $3.50 |
| 52 Week High | $30.00 | $17.63 |
| Indicator | HDL | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 73.73 |
| Support Level | $17.66 | $15.21 |
| Resistance Level | $17.77 | $17.63 |
| Average True Range (ATR) | 0.31 | 0.99 |
| MACD | 0.13 | 0.09 |
| Stochastic Oscillator | 99.34 | 95.42 |
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.